AI Terminal
Theradiag
Report Publication Announcement • Dec 15, 2020
1702_iss_2020-12-15_a7097bcd-b2e1-4b6c-b774-ee6d446583ed.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
THERADIAG announces its 2021 financial calendar
Croissy-Beaubourg, December 15, 2020, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, today announces its schedule for the publication of financial information for 2021.
| Events | Dates* |
|---|---|
| 2020 Full-Year Annual Revenue | Monday February 1, 2021 |
| 2020 Full-Year Results | Monday March 22, 2021 |
| Annual General Meeting | Thursday May 6, 2021 |
| 2021 First-Half Revenue | Monday July 19, 2021 |
| 2021 First-Half Results | Monday September 20, 2021 |
(*) Subject to modifications. Press releases will be published before market opening.
About Theradiag
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.
***
Theradiag pioneered "theranostics" testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up "customized treatment" for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website: www.theradiag.com
Theradiag Bertrand de Castelnau CEO/Managing Director Tel.: +33 (0)1 64 62 10 12 [email protected]
NewCap Financial Communications & Investor Relations Louis-Victor Delouvrier Quentin Massé Tel.: +33 (0)1 44 71 94 94 [email protected]
NewCap Media Relations Nicolas Mérigeau Tel.: +33 (0)1 44 71 94 98 [email protected]r